Open AccessA Randomized, Placebo-Controlled Trial of Citalopram for the Treatment of Major Depression in Children and Adolescents
Author(s) -
Karen Dineen Wagner,
Adelaide S. Robb,
Robert L. Findling,
Jianqing Jin,
Marcelo M. Gutierrez,
William E. Heydorn
Publication year - 2004
Publication title -
american journal of psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.477
H-Index - 353
eISSN - 1535-7228
pISSN - 0002-953X
DOI - 10.1176/appi.ajp.161.6.1079
Subject(s) - citalopram , placebo , discontinuation , depression (economics) , randomized controlled trial , adverse effect , psychology , rating scale , placebo controlled study , major depressive disorder , medicine , serotonin reuptake inhibitor , anesthesia , psychiatry , antidepressant , double blind , anxiety , mood , developmental psychology , alternative medicine , macroeconomics , pathology , economics
Open-label trials with the selective serotonin reuptake inhibitor citalopram suggest that this agent is effective and safe for the treatment of depressive symptoms in children and adolescents. The current study investigated the efficacy and safety of citalopram compared with placebo in the treatment of pediatric patients with major depression.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom